Revenue

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

Revenue

Revenue

The Company recorded the following revenues (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Product sales, net:
ORLADEYO	$	64,711	$	28,374	$	114,097	$	39,312
RAPIVAB	177		4,622		337		4,735
Peramivir	—		434		—		7,254
Total product sales, net	64,888		33,430		114,434		51,301
Royalty revenue	540		128		887		(769)
Milestone revenue	—		15,000		—		15,000
Collaborative and other research and development revenues:
U.S. Department of Health and Human Services	104		1,401		134		3,486
Total collaborative and other research and development revenues	104		1,401		134		3,486
Total revenues	$	65,532	$	49,959	$	115,455	$	69,018